Business Alliance on the New Radiopharmaceutical 'Metastron Injectable' (Japan)
This article was originally published in PharmAsia News
Executive Summary
Nippon Kayaku Co. is partnering with Nihon Medi-Physics. The two companies are teaming up to focus on the Japanese distribution of Metastron Injectable. A radiopharmaceutical developed by GE Healthcare, the Metastron Injectable is designed to treat pain associated with metastasized bone cancer. Under the terms of their partnership, Nippon will focus on how to best market Metastron Injectable to healthcare facilities. Nihon will then concentrate finding best practices for the injection's import and distribution as well as educating medical practitioners on its safe and effective use. (Click here for more
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.